KMDA
Price:
$5.99
Market Cap:
$344.30M
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune therm...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2013-05-31
Stock Exchange
NASDAQ
Ticker
KMDA
According to Kamada Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is 22.19. This represents a change of 2.94% compared to the average of 21.56 of the last 4 quarters.
The mean historical PE Ratio of Kamada Ltd. over the last ten years is -16.25. The current 22.19 PE Ratio has changed -13754.97% with respect to the historical average. Over the past ten years (40 quarters), KMDA's PE Ratio was at its highest in in the September 2022 quarter at 112.75. The PE Ratio was at its lowest in in the September 2017 quarter at -204.69.
Average
-16.25
Median
-0.85
Minimum
-132.11
Maximum
36.07
Discovering the peaks and valleys of Kamada Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 121.08%
Maximum Annual PE Ratio = 36.07
Minimum Annual Increase = -891.63%
Minimum Annual PE Ratio = -132.11
Year | PE Ratio | Change |
---|---|---|
2023 | 36.07 | -146.59% |
2022 | -77.43 | -41.39% |
2021 | -132.11 | -891.63% |
2020 | 16.69 | 34.84% |
2019 | 12.38 | 37.03% |
2018 | 9.03 | -65.80% |
2017 | 26.41 | -189.59% |
2016 | -29.48 | 121.08% |
2015 | -13.33 | 24.16% |
2014 | -10.74 | -100.98% |
The current PE Ratio of Kamada Ltd. (KMDA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-57.82
5-year avg
-28.88
10-year avg
-16.25
Kamada Ltd.’s PE Ratio is less than Lifecore Biomedical, Inc. (28.27), greater than Shuttle Pharmaceuticals Holdings, Inc. (-3.69), greater than Cumberland Pharmaceuticals Inc. (-1.55), less than Ironwood Pharmaceuticals, Inc. (72.33), greater than Mallinckrodt plc (-0.00), greater than Organogenesis Holdings Inc. (-52.13), greater than Lucy Scientific Discovery Inc. (-0.72), greater than Alimera Sciences, Inc. (-20.50), greater than Agile Therapeutics, Inc. (-0.65), greater than Guardion Health Sciences, Inc. (-0.70), greater than Akanda Corp. (-0.02), greater than Evoke Pharma, Inc. (-1.19), greater than Collegium Pharmaceutical, Inc. (10.62), greater than Dr. Reddy's Laboratories Limited (18.68), greater than Pacira BioSciences, Inc. (11.94), greater than Perrigo Company plc (-29.10), greater than Eagle Pharmaceuticals, Inc. (0.27), less than ANI Pharmaceuticals, Inc. (40.06), less than Phibro Animal Health Corporation (372.68), greater than Deciphera Pharmaceuticals, Inc. (-11.74), greater than Prestige Consumer Healthcare Inc. (17.95),
Company | PE Ratio | Market cap |
---|---|---|
28.27 | $220.59M | |
-3.69 | $4.71M | |
-1.55 | $16.07M | |
72.33 | $669.31M | |
-0.00 | $4.52M | |
-52.13 | $396.40M | |
-0.72 | $906.91K | |
-20.50 | $301.29M | |
-0.65 | $10.43M | |
-0.70 | $4.35M | |
-0.02 | $2.20M | |
-1.19 | $4.69M | |
10.62 | $1.05B | |
18.68 | $61.71B | |
11.94 | $758.79M | |
-29.10 | $3.47B | |
0.27 | $9.72M | |
40.06 | $1.18B | |
372.68 | $906.07M | |
-11.74 | $2.21B | |
17.95 | $3.66B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kamada Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Kamada Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Kamada Ltd.'s PE Ratio?
How is the PE Ratio calculated for Kamada Ltd. (KMDA)?
What is the highest PE Ratio for Kamada Ltd. (KMDA)?
What is the 3-year average PE Ratio for Kamada Ltd. (KMDA)?
What is the 5-year average PE Ratio for Kamada Ltd. (KMDA)?
How does the current PE Ratio for Kamada Ltd. (KMDA) compare to its historical average?